Chung-Hsuen Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chung-Hsuen Wu has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Steven R. Erickson
College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
8 shared publications Fang-Ju Lin
Natl Taiwan Univ, Sch Pharm, Taipei, Taiwan
6 shared publications- Chih-Yuan Wang
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
5 shared publications - Chun-Tse Hung
Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA
5 shared publications Aaron J. Katz
Univ Kansas, Dept Populat Hlth, Sch Med, Kansas City, KS USA
4 shared publicationsHsin-Yi Huang
4 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- p. 1
Publisher Correction: Review Performance of New Active Substances in Taiwan: A 10-Year Retrospective Analysis (2015–2024)
- 7 September 2026
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- p. 1
Open AccessPublisher Correction: Review Performance of New Active Substances in Taiwan: A 10-Year Retrospective Analysis (2015–2024)
- Open Access
- 1 September 2026
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- p. 1-16
Review Performance of New Active Substances in Taiwan: A 10-Year Retrospective Analysis (2015–2024)
Background: Since 2011, the Taiwan Food and Drug Administration (TFDA) has established various facilitated regulatory pathways (FRPs, including expedited and accelerated review frameworks) for new drug applications. In 2017 and 2019, TFDA implemented the Refuse to File (RTF) mechanism and conducted a comprehensive revision of FRPs, respectively. This study aims to evaluate the outcomes of these reforms from 2015 to 2024, focusing on New Active Substance (NAS) approvals, pathway utilization, and international comparison. Methods: NAS approvals between 2015 and 2024 were analyzed using TFDA’s internal regulatory database, with U.S. Food and Drug Administration (US FDA), European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (Japan’s PMDA) data obtained from public sources. Analyses and visualizations were conducted with R. Results: Following the 2017 and 2019 reforms, the on-time rate for the 360-day standard pathway surged from 19.0% of 21 cases in 2015 to 100% in 16 cases in 2024. A distinct structural shift toward FRPs was observed, as the proportion of standard applications declined from 80.4% to 56.4%. A contextual comparison of median approval times indicated that TFDA’s timelines were broadly comparable to those of the EMA and moved closer to those of the US FDA and Japan’s PMDA over the study period. Conclusions: The TFDA review timelines became substantially more predictable, and the pathway distribution shifted toward FRPs. These changes followed the 2017 and 2019 reforms and reflect their combined contribution rather than any single mechanism. The cross-agency figures reported here serve as a general point of reference rather than a direct efficiency comparison, given differences in product mix, therapeutic areas, pathway eligibility criteria, submission timing and clock-stop mechanisms. Building on these developments, the forthcoming reliance pilot program is expected to further support patient access and regulatory resilience.
- 1 September 2026
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- p. 1-16
Open AccessReview Performance of New Active Substances in Taiwan: A 10-Year Retrospective Analysis (2015–2024)
Background: Since 2011, the Taiwan Food and Drug Administration (TFDA) has established various facilitated regulatory pathways (FRPs, including expedited and accelerated review frameworks) for new drug applications. In 2017 and 2019, TFDA implemented the Refuse to File (RTF) mechanism and conducted a comprehensive revision of FRPs, respectively. This study aims to evaluate the outcomes of these reforms from 2015 to 2024, focusing on New Active Substance (NAS) approvals, pathway utilization, and international comparison. Methods: NAS approvals between 2015 and 2024 were analyzed using TFDA’s internal regulatory database, with U.S. Food and Drug Administration (US FDA), European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (Japan’s PMDA) data obtained from public sources. Analyses and visualizations were conducted with R. Results: Following the 2017 and 2019 reforms, the on-time rate for the 360-day standard pathway surged from 19.0% of 21 cases in 2015 to 100% in 16 cases in 2024. A distinct structural shift toward FRPs was observed, as the proportion of standard applications declined from 80.4% to 56.4%. A contextual comparison of median approval times indicated that TFDA’s timelines were broadly comparable to those of the EMA and moved closer to those of the US FDA and Japan’s PMDA over the study period. Conclusions: The TFDA review timelines became substantially more predictable, and the pathway distribution shifted toward FRPs. These changes followed the 2017 and 2019 reforms and reflect their combined contribution rather than any single mechanism. The cross-agency figures reported here serve as a general point of reference rather than a direct efficiency comparison, given differences in product mix, therapeutic areas, pathway eligibility criteria, submission timing and clock-stop mechanisms. Building on these developments, the forthcoming reliance pilot program is expected to further support patient access and regulatory resilience.
- 19 August 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (9) , e70194
Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study
Background: Antihyperglycemic drugs have shown benefits in asthma control. However, evidence regarding the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) in reducing asthma exacerbations remains inconsistent. Objective: We aimed to evaluate the association of GLP‐1 RAs versus SGLT‐2is with risk of asthma exacerbation among patients with asthma and type 2 diabetes. Methods: This retrospective cohort study used electronic health record data from the TriNetX Global Collaborative Network. Adults with asthma and type 2 diabetes who initiated GLP‐1 RAs or SGLT‐2is between January 1, 2013, and June 30, 2024, were included. The primary outcome was the time to first asthma exacerbation. Secondary outcomes included first episode of asthma symptoms or systemic corticosteroid use. Patients were followed for up to 6 months in the main analysis. Propensity score matching was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Results: A total of 100,746 patients were included, comprising 61,955 GLP‐1 RA users and 38,791 SGLT‐2i users. After 1:1 matching, both groups consisted of 28,831 patients. GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared with SGLT‐2is (HR, 0.88; 95% CI, 0.85–0.91). GLP‐1 RAs were also associated with a decreased risk of experiencing asthma symptoms (HR, 0.89; 95% CI, 0.82–0.97) and receiving systemic corticosteroids (HR, 0.79; 95% CI, 0.76–0.82). Results from sensitivity analyses were generally consistent, but the association for asthma exacerbation was not observed when follow‐up was extended to 1 year (HR, 0.95; 95% CI, 0.89–1.02). Conclusion: GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared to SGLT‐2is among patients with asthma and type 2 diabetes. As these findings reflect associations rather than causal effects, further investigation through randomized trials is warranted. image
- 19 August 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (9) , e70194
Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study
Background: Antihyperglycemic drugs have shown benefits in asthma control. However, evidence regarding the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) in reducing asthma exacerbations remains inconsistent. Objective: We aimed to evaluate the association of GLP‐1 RAs versus SGLT‐2is with risk of asthma exacerbation among patients with asthma and type 2 diabetes. Methods: This retrospective cohort study used electronic health record data from the TriNetX Global Collaborative Network. Adults with asthma and type 2 diabetes who initiated GLP‐1 RAs or SGLT‐2is between January 1, 2013, and June 30, 2024, were included. The primary outcome was the time to first asthma exacerbation. Secondary outcomes included first episode of asthma symptoms or systemic corticosteroid use. Patients were followed for up to 6 months in the main analysis. Propensity score matching was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Results: A total of 100,746 patients were included, comprising 61,955 GLP‐1 RA users and 38,791 SGLT‐2i users. After 1:1 matching, both groups consisted of 28,831 patients. GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared with SGLT‐2is (HR, 0.88; 95% CI, 0.85–0.91). GLP‐1 RAs were also associated with a decreased risk of experiencing asthma symptoms (HR, 0.89; 95% CI, 0.82–0.97) and receiving systemic corticosteroids (HR, 0.79; 95% CI, 0.76–0.82). Results from sensitivity analyses were generally consistent, but the association for asthma exacerbation was not observed when follow‐up was extended to 1 year (HR, 0.95; 95% CI, 0.89–1.02). Conclusion: GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared to SGLT‐2is among patients with asthma and type 2 diabetes. As these findings reflect associations rather than causal effects, further investigation through randomized trials is warranted. image
- 17 July 2026
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 107 (11) , 3290-3297
Association of Combined Physical and Cognitive Rehabilitation With Poststroke Dementia: A US Multicenter Retrospective Cohort Study
- 17 July 2026
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 107 (11) , 3290-3297
Association of Combined Physical and Cognitive Rehabilitation With Poststroke Dementia: A US Multicenter Retrospective Cohort Study
- Open Access
- 5 May 2026
- Published by Taylor & Francis in Journal of Asthma
- p. 1-10
Evaluating the association between omalizumab use and adverse fetal outcomes among pregnant women with asthma: a population-based retrospective cohort study
This study aimed to evaluate the association between omalizumab use during pregnancy and the risk of adverse fetal outcomes among pregnant women with asthma. This population-based retrospective cohort study was conducted using data from the 2010-2022 National Health Insurance Research Database and the Birth Certification Application in Taiwan. The study population was pregnant women with asthma. An active-comparator design was employed. Pregnant women who received at least one dose of omalizumab during pregnancy were assigned as the exposure group, while those having at least one prescription for inhaled corticosteroid (ICS) during pregnancy were assigned as the control group. The study outcome was adverse fetal outcomes. Propensity score matching was used to adjust for measurable confounders. Conditional logistic regression models were used to estimate the risk of adverse fetal outcomes. A total of 4,416 pregnant women with asthma were included, with 16 (0.1%) receiving omalizumab and 4,410 (99.9%) using ICS during pregnancy. The risk of adverse fetal outcomes, including pre-term birth (OR, 1.74; 95% CI, 0.46-6.63), low birth weight (OR, 1.04; 95% CI, 0.22-4.87), small for gestational age (OR, 1.11; 95% CI, 0.14-8.98), did not differ between omalizumab and ICS users. Omalizumab was not associated with an increased risk of adverse fetal outcomes among pregnant women with asthma. Further investigation with a larger sample of omalizumab users is warranted.
- 5 May 2026
- Published by Taylor & Francis in Journal of Asthma
- p. 1-10
Open AccessEvaluating the association between omalizumab use and adverse fetal outcomes among pregnant women with asthma: a population-based retrospective cohort study
This study aimed to evaluate the association between omalizumab use during pregnancy and the risk of adverse fetal outcomes among pregnant women with asthma. This population-based retrospective cohort study was conducted using data from the 2010-2022 National Health Insurance Research Database and the Birth Certification Application in Taiwan. The study population was pregnant women with asthma. An active-comparator design was employed. Pregnant women who received at least one dose of omalizumab during pregnancy were assigned as the exposure group, while those having at least one prescription for inhaled corticosteroid (ICS) during pregnancy were assigned as the control group. The study outcome was adverse fetal outcomes. Propensity score matching was used to adjust for measurable confounders. Conditional logistic regression models were used to estimate the risk of adverse fetal outcomes. A total of 4,416 pregnant women with asthma were included, with 16 (0.1%) receiving omalizumab and 4,410 (99.9%) using ICS during pregnancy. The risk of adverse fetal outcomes, including pre-term birth (OR, 1.74; 95% CI, 0.46-6.63), low birth weight (OR, 1.04; 95% CI, 0.22-4.87), small for gestational age (OR, 1.11; 95% CI, 0.14-8.98), did not differ between omalizumab and ICS users. Omalizumab was not associated with an increased risk of adverse fetal outcomes among pregnant women with asthma. Further investigation with a larger sample of omalizumab users is warranted.
- Open Access
- 9 September 2025
- Published by Wiley in Respirology
- Vol. 31 (1) , 32-41
The Association Between Use of Inhaled Corticosteroids and Long‐Acting Beta2‐Agonists During Pregnancy and Adverse Fetal Outcomes
Background and Objective: Women with asthma should continue controller therapy during pregnancy, but current evidence on the effects of inhaled corticosteroids (ICS) and long‐acting beta2‐agonists (LABA) on adverse fetal outcomes remains unclear. Methods: This was a population‐based retrospective cohort study. Data were derived from the Health and Welfare Database, Birth Certificate Application, and Maternal and Child Health Database in Taiwan, from January 1, 2007 to December 31, 2018. Pregnant women with asthma were enrolled. Three independent variables included ICS use, ICS dose–response effects, and LABA use during pregnancy. Adverse fetal outcomes included low birth weight, small for gestational age, preterm birth, and congenital anomalies. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to adjust for confounders, including sociodemographics, comorbidities, comedications, and asthma severity. Logistic regression models were used to calculate adjusted odds ratios (aORs). Results: There were 4538 pregnant women with asthma enrolled in this study. After adjustment, neither ICS nor LABA use was significantly associated with any adverse fetal outcomes. However, among women exposed to ICS, high‐dose ICS use during pregnancy was associated with a significantly higher risk of congenital anomalies (aOR: 3.87; 95% CI: 1.29–11.60) within 1 year of delivery. Conclusions: ICS or LABA use during pregnancy was not associated with the risk of adverse fetal outcomes. Pregnant women with asthma should be advised to maintain controller therapy and avoid potential allergens to reduce the need for high‐dose ICS. image
- 9 September 2025
- Published by Wiley in Respirology
- Vol. 31 (1) , 32-41
Open AccessThe Association Between Use of Inhaled Corticosteroids and Long‐Acting Beta2‐Agonists During Pregnancy and Adverse Fetal Outcomes
Background and Objective: Women with asthma should continue controller therapy during pregnancy, but current evidence on the effects of inhaled corticosteroids (ICS) and long‐acting beta2‐agonists (LABA) on adverse fetal outcomes remains unclear. Methods: This was a population‐based retrospective cohort study. Data were derived from the Health and Welfare Database, Birth Certificate Application, and Maternal and Child Health Database in Taiwan, from January 1, 2007 to December 31, 2018. Pregnant women with asthma were enrolled. Three independent variables included ICS use, ICS dose–response effects, and LABA use during pregnancy. Adverse fetal outcomes included low birth weight, small for gestational age, preterm birth, and congenital anomalies. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to adjust for confounders, including sociodemographics, comorbidities, comedications, and asthma severity. Logistic regression models were used to calculate adjusted odds ratios (aORs). Results: There were 4538 pregnant women with asthma enrolled in this study. After adjustment, neither ICS nor LABA use was significantly associated with any adverse fetal outcomes. However, among women exposed to ICS, high‐dose ICS use during pregnancy was associated with a significantly higher risk of congenital anomalies (aOR: 3.87; 95% CI: 1.29–11.60) within 1 year of delivery. Conclusions: ICS or LABA use during pregnancy was not associated with the risk of adverse fetal outcomes. Pregnant women with asthma should be advised to maintain controller therapy and avoid potential allergens to reduce the need for high‐dose ICS. image
- 25 June 2025
- Published by Springer Nature in Infection
- Vol. 53 (6) , 2523-2531
Evaluating the associations among asthma, asthma control and long COVID in U.S. adults
Objective This study aimed to evaluate (1) the association between asthma and long COVID among U.S. adults and (2) the association between asthma control and long COVID among U.S. adults with asthma. Methods Data from the 2023 National Health Interview Survey were used. Adults aged ≥ 18 years were included. Asthma control was measured by the history of asthma attacks and emergency room (ER) visits for asthma. Multivariable logistic regression models were used to evaluate the associations. A sensitivity analysis was performed by stratifying long COVID severity. Results A total of 258,237,552 adults were included in this study. The prevalence of long COVID among U.S. adults in 2023 was 8.2%. When stratified by the presence of asthma, the prevalence was 15.2% for those with asthma and 7.6% for those without asthma (P < 0.01). After adjusting for covariates, adults with asthma had higher odds of long COVID than those without asthma (OR, 1.58; 95% CI, 1.37–1.83). This association was consistent across long COVID severity levels. Poor asthma control was associated with increased odds of long COVID (asthma attacks: OR, 1.47; 95% CI, 1.09–1.97; ER visits for asthma: OR, 1.52; 95% CI, 1.02–2.27). Conclusion Asthma was associated with increased odds of long COVID. Patients with poorly controlled asthma were associated with increased odds of long COVID. From a clinical perspective, it is crucial to proactively identify patients with asthma at increased risk of long COVID, especially those with certain comorbidities. Future research on specific symptoms and the duration of long COVID among patients with asthma will benefit clinical practice.
- 25 June 2025
- Published by Springer Nature in Infection
- Vol. 53 (6) , 2523-2531
Evaluating the associations among asthma, asthma control and long COVID in U.S. adults
Objective This study aimed to evaluate (1) the association between asthma and long COVID among U.S. adults and (2) the association between asthma control and long COVID among U.S. adults with asthma. Methods Data from the 2023 National Health Interview Survey were used. Adults aged ≥ 18 years were included. Asthma control was measured by the history of asthma attacks and emergency room (ER) visits for asthma. Multivariable logistic regression models were used to evaluate the associations. A sensitivity analysis was performed by stratifying long COVID severity. Results A total of 258,237,552 adults were included in this study. The prevalence of long COVID among U.S. adults in 2023 was 8.2%. When stratified by the presence of asthma, the prevalence was 15.2% for those with asthma and 7.6% for those without asthma (P < 0.01). After adjusting for covariates, adults with asthma had higher odds of long COVID than those without asthma (OR, 1.58; 95% CI, 1.37–1.83). This association was consistent across long COVID severity levels. Poor asthma control was associated with increased odds of long COVID (asthma attacks: OR, 1.47; 95% CI, 1.09–1.97; ER visits for asthma: OR, 1.52; 95% CI, 1.02–2.27). Conclusion Asthma was associated with increased odds of long COVID. Patients with poorly controlled asthma were associated with increased odds of long COVID. From a clinical perspective, it is crucial to proactively identify patients with asthma at increased risk of long COVID, especially those with certain comorbidities. Future research on specific symptoms and the duration of long COVID among patients with asthma will benefit clinical practice.
- Open Access
Cost-related non-adherence to medications among adults with asthma in the USA, 2011–2022
Background Uncontrolled asthma is possibly caused by medication non-adherence, and financial hardship can be a major contributor to non-adherence. Since economic conditions and asthma management have changed over time, a comprehensive investigation of cost-related medication non-adherence (CRN) among adults with asthma is crucial. Objective To evaluate trends, prevalence and determinants of CRN, and its impact on asthma control among US adults with asthma. Methods Data from 2011 to 2022 National Health Interview Survey were used. Joinpoint regression analysis was used to evaluate trends in the prevalence of CRN. A multivariable logistic regression model was used to identify factors associated with CRN. Two additional multivariable logistic regression models were used to examine associations between CRN and asthma-related adverse events, including asthma attacks and emergency room (ER) visits for asthma. Results A total of 30 793 adults with asthma were included, representing 8.1% (19.38 million) of the US population. From 2011 to 2022, a declining trend in the prevalence of CRN among US adults with asthma was observed. Approximately every one in six adults with asthma was non-adherent to medications due to cost. Several factors, including demographics and comorbidities, were associated with CRN. Adults with asthma who had CRN were at an increased risk of experiencing asthma attacks (adjusted OR, 1.95; 95% CI 1.78 to 2.13) and ER visits for asthma (adjusted OR, 1.63; 95% CI 1.44 to 1.84). Conclusion Since asthma is one of the leading chronic diseases, the burden of cost-related non-adherence to medications highlights the need for appropriate policies and social supports to address such problems.
Open AccessCost-related non-adherence to medications among adults with asthma in the USA, 2011–2022
Background Uncontrolled asthma is possibly caused by medication non-adherence, and financial hardship can be a major contributor to non-adherence. Since economic conditions and asthma management have changed over time, a comprehensive investigation of cost-related medication non-adherence (CRN) among adults with asthma is crucial. Objective To evaluate trends, prevalence and determinants of CRN, and its impact on asthma control among US adults with asthma. Methods Data from 2011 to 2022 National Health Interview Survey were used. Joinpoint regression analysis was used to evaluate trends in the prevalence of CRN. A multivariable logistic regression model was used to identify factors associated with CRN. Two additional multivariable logistic regression models were used to examine associations between CRN and asthma-related adverse events, including asthma attacks and emergency room (ER) visits for asthma. Results A total of 30 793 adults with asthma were included, representing 8.1% (19.38 million) of the US population. From 2011 to 2022, a declining trend in the prevalence of CRN among US adults with asthma was observed. Approximately every one in six adults with asthma was non-adherent to medications due to cost. Several factors, including demographics and comorbidities, were associated with CRN. Adults with asthma who had CRN were at an increased risk of experiencing asthma attacks (adjusted OR, 1.95; 95% CI 1.78 to 2.13) and ER visits for asthma (adjusted OR, 1.63; 95% CI 1.44 to 1.84). Conclusion Since asthma is one of the leading chronic diseases, the burden of cost-related non-adherence to medications highlights the need for appropriate policies and social supports to address such problems.
- 1 November 2023
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 98 (11) , 1602-1612
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke
- 1 November 2023
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 98 (11) , 1602-1612
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke